More than 200 innovative life science firms will present their products and strategies to top investors at Biotech Showcase TM on January 9-11, 2012, to be held at the Parc 55 Wyndham Hotel - Union Square in San Francisco. Co-produced by EBD Group and Demy-Colton Life Science Advisors, the event is expected to attract upwards of 1,300 attendees and will play host to leading investment firms such as Abingworth Management, Aescap Venture, Atlas Ventures, Bay City Capital, Index Ventures, Goldman Sachs, LifeTech Capital, Life Science Angels, Sikich Investment Banking, Pappas Ventures, Sofinnova Ventures, and Yorkville Advisors.
"Each year during the second week of January, San Francisco becomes the mecca for life science companies and investors. Biotech Showcase is the home base for the innovator class of life science companies, and the firms that aim to invest in or partner with them," said Carola Schropp, President of EBD Group. "The event is perfectly contoured to help raise the profile of presenting companies among qualified investors, and facilitate productive networking between them."
Now in its fourth year, Biotech Showcase has emerged as the event where professional and private investors can identify and meet with the companies driving innovation in the life science industry.
"Biotech Showcase is the new "˜H&Q,´ meaning that this is where tomorrow´s market leaders can be found. With over 200 presenting companies, top-flight investment firms and 1,300 delegates expected to attend, Biotech Showcase is the platform that will help many companies get to their next value inflection point," added Schropp.
Biotech Showcase participants include private and public equity investors, analysts, bankers, biopharmaceutical and life science industry executives and other industry professionals. The program includes lunch plenary sessions featuring top industry leaders and innovators speaking on industry- and time-relevant topics, as well as presentations from both private and public companies.
For more information or to register for Biotech Showcase, go to http://www.ebdgroup.com/bts/index.php.
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group´s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group´s conferences are run with the support of leading corporations and international trade associations and include:
- BIO-Europe® and BIO-Europe Spring®, Europe´s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
- BioPharm America TM, the fastest growing partnering event in North America
- EuroMedtech TM, EBD Group´s partnering event for the innovative medical technology industry
- BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
- ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
- Partnering for Global Impact TM, a new partnering conference providing an innovative forum to partner, identify and generate social and philanthropic investment and funding opportunities
- Biotech Showcase TM, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
EBD Group´s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences at industry events.
Outside of the conference format, EBD Group´s consultants provide hands-on assistance for firms seeking to in- or out-license products and technologies.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com.
About Demy-Colton Life Science Advisors
Demy-Colton is focused exclusively on facilitating the growth of the life science industry. Sara Jane Demy, the principal of Demy-Colton, is a leader at designing and developing high-value added programs and services to address the business needs of the biotechnology industry.
